Adherence to Aromatase Inhibitors: The Role of Partners

Completed

Conditions studied: Breast Cancer Survivors

In brief

This is a qualitative study which explores the role that partners play in breast cancer survivors adherence to aromatase inhibitors and management of their side effects. Both patients and their partners will be interviewed (separately) in order to capture multiple perspectives. The target number of subjects is 64 (32 patients and 32 partners). The primary method of data collection will be face-to-face semi-structured interviews. These interviews will be audio-recorded.

Key facts

Study ID

NCT02753985

Run by

Abramson Cancer Center at Penn Medicine

People needed

40

Starts

2014-07-01

Expected to finish

2016-04-22

Last updated by the study team

2019-07-23

Who can join

Age: 18 and older. Sex: female. Healthy volunteers: accepted.

You may qualify if…

• Women and partners of women with stage I-III breast cancer who
• have completed primary cancer treatments (surgery, chemotherapy, radiotherapy)
• have experienced AI side effects
• live with a romantic partner.

Where it is running

• Abramson Cancer Center of the University of Pennsylvania — Philadelphia, Pennsylvania, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.